title: Myricetin Prevents Alveolar Bone Loss in an Experimental Ovariectomized Mouse Model of Periodontitis.
abstract: Periodontitis is a common chronic inflammatory disease, which leads to alveolar bone resorption. Healthy and functional alveolar bone, which can support the teeth and enable their movement, is very important for orthodontic treatment. Myricetin inhibited osteoclastogenesis by suppressing the expression of some genes, signaling pathways, and cytokines. This study aimed to investigate the effects of myricetin on alveolar bone loss in an ovariectomized (OVX) mouse model of periodontitis as well as in vitro osteoclast formation and bone resorption. Twenty-four healthy eight-week-old C57BL/J6 female mice were assigned randomly to four groups: phosphate-buffered saline (PBS) control (sham) OVX + ligature + PBS (vehicle), and OVX + ligature + low or high (2 or 5 mg∙kg(-1)∙day(-1), respectively) doses of myricetin. Myricetin or PBS was injected intraperitoneally (i.p.) every other day for 30 days. The maxillae were collected and subjected to further examination, including micro-computed tomography (micro-CT), hematoxylin and eosin (H&E) staining, and tartrate-resistant acid phosphatase (TRAP) staining; a resorption pit assay was also performed in vitro to evaluate the effects of myricetin on receptor activator of nuclear factor κ-B ligand (RANKL)-induced osteoclastogenesis. Myricetin, at both high and low doses, prevented alveolar bone resorption and increased alveolar crest height in the mouse model and inhibited osteoclast formation and bone resorption in vitro. However, myricetin was more effective at high dose than at low dose. Our study demonstrated that myricetin had a positive effect on alveolar bone resorption in an OVX mouse model of periodontitis and, therefore, may be a potential agent for the treatment of periodontitis and osteoporosis.
authors.affiliation: Department of Orthodontics, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, 639 Zhizaoju Road, Shanghai 200011, China. huangjialiang1985@163.com.
authors.forename: Jialiang
authors.initials: J
authors.lastname: Huang
authors.affiliation: Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedics, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200011, China. challengewu1988@163.com.
authors.forename: Chuanlong
authors.initials: C
authors.lastname: Wu
authors.affiliation: Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedics, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200011, China. poetian@163.com.
authors.forename: Bo
authors.initials: B
authors.lastname: Tian
authors.affiliation: Department of Orthodontics, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, 639 Zhizaoju Road, Shanghai 200011, China. xzhouaa@163.com.
authors.forename: Xiao
authors.initials: X
authors.lastname: Zhou
authors.affiliation: Department of Orthodontics, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, 639 Zhizaoju Road, Shanghai 200011, China. nianmaaa@163.com.
authors.forename: Nian
authors.initials: N
authors.lastname: Ma
authors.affiliation: Department of Orthodontics, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, 639 Zhizaoju Road, Shanghai 200011, China. qianyf1960@163.com.
authors.forename: Yufen
authors.initials: Y
authors.lastname: Qian
mesh_terms: D016301:Alveolar Bone Loss / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control*; D000818:Animals; D002460:Cell Line; D005260:Female; D005419:Flavonoids / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D007274:Injections, Intraperitoneal; D008437:Maxilla / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008439:Maxillary Diseases / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control*; D051379:Mice; D008810:Mice, Inbred C57BL; D010012:Osteogenesis; D010052:Ovariectomy / Q000009:adverse effects; D053245:RANK Ligand / Q000378:metabolism
chemical_list: D005419:Flavonoids; D053245:RANK Ligand; C040015:myricetin
keywords: alveolar bone resorption; myricetin; osteoclast formation; periodontitis